Federated Hermes’s Aquestive Therapeutics AQST Stock Holding History

Federated Hermes’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9M	Buy	3,112,561 +172,222	+6%	+$725K	0.02%	605
2026 Q1	$12.2M	Buy	2,940,339 +907,517	+45%	+$3.68M	0.02%	581
2025 Q4	$13.1M	Buy	2,032,822 +1,249,044	+159%	+$7.78M	0.02%	552
2025 Q3	$4.38M	Buy	+783,778	New	+$3.39M	0.01%	765
2024 Q2	–	Sell	-1,404	Closed	-$5.98K	–	2026
2024 Q1	$5.98K	Sell	1,404 -1,045	-43%	-$3.48K	﹤0.01%	1820
2023 Q4	$4.95K	Buy	2,449 +204	+9%	+$360	﹤0.01%	1853
2023 Q3	$3.44K	Hold	2,245	–	–	﹤0.01%	1922
2023 Q2	$3.7K	Buy	+2,245	New	+$4.06K	﹤0.01%	1935
2020 Q4	–	Sell	-58	Closed	-$1K	–	2236
2020 Q3	$1K	Buy	+58	New	+$379	﹤0.01%	2134

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Federated Hermes's AQST Position: Q2 2026 in Review

Federated Hermes increased its Aquestive Therapeutics (AQST) stake by 5.9% in Q2 2026, buying an estimated $725K and bringing the position to 3,112,561 shares worth $12.9M. The position accounts for 0.02% of the portfolio, ranked #605.

Federated Hermes first reported a position in AQST in Q3 2020 and has held it in 9 quarters since. The position peaked at $13.1M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Federated Hermes held 3,112,561 shares of Aquestive Therapeutics worth $12.9M as of Q2 2026.
Federated Hermes bought 172,222 Aquestive Therapeutics shares in Q2 2026, an estimated $725K.
Aquestive Therapeutics made up 0.02% of Federated Hermes's portfolio in Q2 2026, its #605 holding.
Federated Hermes first reported a position in Aquestive Therapeutics in Q3 2020 and has held it in 9 quarters since.
Federated Hermes's Aquestive Therapeutics position peaked at $13.1M in Q4 2025.
185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.